Regent Lifesciences is an innovation-driven company dedicated to new drug discovery and patient-centric medical device development. Headquartered in Dubai, the company places a strong emphasis on inhalation science, pioneering first-in-the-world Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) platforms designed to elevate precision, performance, and patient outcomes.

The company specializes in end-to-end development—from early concept and formulation through prototyping to manufacturing—providing comprehensive solutions that bridge the gap between scientific innovation and commercial viability. This integrated approach enables Regent to maintain rigorous quality standards while accelerating the path from laboratory to patient.

Regent Lifesciences actively partners with pharmaceutical companies seeking advanced drug-research capabilities or innovative device technologies. By combining deep scientific expertise with cutting-edge engineering, the company delivers tailored solutions that address unmet medical needs and improve therapeutic delivery.

With a commitment to shaping the next generation of therapies and delivery systems, Regent welcomes collaboration with forward-thinking organizations across the global healthcare landscape. Whether developing novel formulations, refining device mechanics, or exploring new therapeutic applications, Regent Lifesciences stands at the forefront of respiratory and inhalation innovation—driving meaningful advancements that enhance patient care worldwide.